

CASE 085

AUTHOR: Ruchi Bhajewala

ACKNOWLEDGEMENT: Dr. Shivani Sharma, Dr. Hari Goyal, Dr. Sambit Mohanty.

CASE HISTORY:

The patient, a 42-years-old woman who presented with a left breast mass and mastalgia for two months' duration. She underwent a left breast lumpectomy with axillary dissection. On histopathologic evaluation, a diagnosis of an invasive ductal carcinoma, histologic grade 3 was rendered. Fifteen lymph nodes including two sentinel lymph nodes were negative; however, Lymphovascular invasion was present. No in situ component was identified. The overall pathologic stage was pT2N0. The tumor had a hormone positive and HER2 negative profile. To check for recurrent risk and further long term treatment plan inclusive of benefits from chemotherapy and hormonal therapy regimen for this patient, a Digistain test was performed.

TITLE:

Digistain a new age artificial intelligence (AI) based spectrometry analysis for personalized breast cancer recurrent risk and therapy guidance.

INTRODUCTION:

Digistain is a patented risk profiling test for hormone receptor-positive breast cancer patients and has identified patients who could forego adjuvant chemotherapy. It reports the likelihood of breast cancer recurrence when treated with hormonal therapy alone. The test is suitable for women with Stage 1 or 2 invasive breast cancer that is hormone receptor positive, Her2/neu - negative, and with no more than 3 positive lymph nodes. Digistain Prognostic Score uses a proprietary optical scan of the tumor tissue to capture a unique spectral signature of the tumor. It then performs an analysis on over 10,000 data points factoring in other clinicopathological factors to compute a risk of recurrence.